Icon
+91 94997 68112
Login Register

Ofev - (100, 150 mg; Capsule, Oral)

Nintedanib Boehringer Ingelheim
100, 150 mg; Capsule, Oral
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
Less Than 5
None None
Ofev is indicated for the treatment of idiopathic pulmonary fibrosis (IPF). Ofev is indicated for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype
Yes
* **** ** ***** ** * ******* *********, *** *** ******* ** ********* *** *******. ** *** **, **** ****** ******** * ********* ******** **** *** *** ********** ******** ***** *** *****. ******** **** ******** * ********* ******** ** *** **, ****. ** *** ** **** **** *** ******** ****** ** *** ********** ********* **** * ****-*** *** **** ***** ** *** ******** ******* **** ** ****** ****** ** *** *, ****. **** ********* **** ***** * ****-** ** *** ******* '*** *** '***. ** *** **** ********* **** ** ********** *** ********* ******* ****** ****** ** ******** ** *** *** ****** (**********) . ** *** *, **** ***** ***** * ****** ********* ******* **********. ** *** ******* * *********** ********* ** ***-************ ** *** ******* ** ***** ** *** ***** * ****-** ('*** & '***). ** ****** ** ***** * **** *** ** '*** *** '***. ** *** **, **** ***** ******** * ********* ******** *** ********** ******** . ** ********** *********** ** ********* *** *** ****. ** *** **, **** ***** ******** * ********* ******** *** ********** ******** . ** ********** *********** ** ********* *** *** ****.
Ofev Patent 1 Patent 2 Patent 3 Patent 4 Patent 5
****** (*****) **** *** **** *** *** ********* *** ********* ****** ***
******** **** *** **** *** *** ********* *** ********* ****** ***
***** **** *** **** *** ******* ******* **** ***
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
****** (*****) *** \ ********* -**- *** ********* ********* ******** ** *** *, ****
******** *** \ ********* -**- *** ********* ********* ******** ** *** *, ****
***** ** \ ** -**- ******* **** ** *** *, ****
  1. *** **, **** : * ****-** ** ***** *** ***** *** * *** *********. ****** *** ******** **** ***** ** ** * ** *** ****. *** ***** * *** ********* ****** *******.
  2. *** **, **** : ******** ******** ********* ******** *** ********** ********. *** '*** ****** *** ***** ** ** ****** ***.
  3. *** *, **** : ****** ******** ********* ******** *** ********** ********. *** '*** ****** *** ***** ** ** ****** ***.
  4. *** *, **** : ***** ***** * **** ******* ********** ******* * *********** ********* ** ***-************ ** ******* '*** *** '***
  5. *** **, **** : ***** ******** * ********* ******** *** ********** ******** . ** ********** *********** ** ********* *** *** ****.
  6. *** **, **** : * ******** ******* ********* *** ********** ******* ***** *** ********** ** *****.
  7. *** **, **** : ********** ******* ***** *** ********** ** ******* *****. *****'* **** ***** ** ** ***-**********
  8. *** **, **** : ***** ******** * ********* ******** *** ********** ******** . ** ********** *********** ** ********* *** *** ****.

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.